NEK2通过AKT/p-AKT途径促进骨髓瘤的进展,并与FoxM1相互作用
Xin Tan1, Xiaojing Liang1, Yi Feng1
1Department of Pathology, School of Basic Medical Science, Anhui Medical University, Hefei, 230032, People's Republic of China.
Medical oncology (Northwood, London, England)
|March 19, 2025
概括
与NIMA相关的激酶2 (NEK2) 通过激活AKT/p-AKT通路来促进骨髓瘤的进展和化学抵抗. 抑制NEK2抑制了瘤生长,转移,并提高了骨髓瘤化学疗法的有效性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 骨髓瘤是一种主要的骨癌,其特点是高度侵入性和转移性.
- 化疗耐药性是治疗骨髓瘤的一个重大挑战.
- 叉头盒蛋白M1 (FoxM1) 促进骨髓瘤的进展,但NIMA相关酶2 (NEK2) 的作用尚不清楚.
研究的目的:
- 研究NEK2在骨髓瘤中的功能作用和分子机制.
- 探索FoxM1和NEK2在骨髓瘤中的关系.
- 确定NEK2对骨髓瘤扩散,迁移,入侵,亡和化学敏感性的影响.
主要方法:
- 皮尔森对GEO数据集 (GSE33382) 的相关性分析,用于FoxM1和NEK2表达式.
- 同免疫沉 (Co-IP) 证实了FoxM1-NEK2的相互作用.
- 在体外研究使用骨髓瘤细胞系 (HOS,U2OS) 与NEK2调制 (抑制,敲击,过度表达) 和西部斑点,CCK-8,殖民地形成,Transwell和流动细胞计测试.
主要成果:
- 观察到NEK2和FoxM1表达之间的正相关性.
- NEK2的淘汰抑制了骨髓瘤的扩散,迁移和入侵,同时增强了西斯普拉丁的敏感性和促进了亡.
- 过度表达NEK2导致恶性瘤增加和化学敏感性降低,通过AKT/p-AKT通路进行介导.
结论:
- 在促进骨髓瘤的扩散,入侵,迁移和化学抵抗方面,NEK2起着至关重要的作用.
- AKT/p-AKT通路的NEK2激活是驱动骨髓瘤进展的关键机制.
- FoxM1可能调节骨髓瘤中NEK2的功能,这表明NEK2-FoxM1-AKT轴的潜在治疗向.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
MAPK Signaling Cascades
5.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K


